D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2

Nature Communications

Volumn 6, Issue , 2015, Pages

  Lin, An Ping ^a   Abbas, Saman ^a   Kim, Sang Woo ^a,f   Ortega, Manoela ^a   Bouamar, Hakim ^a   Escobedo, Yissela ^a   Varadarajan, Prakash ^a   Qin, Yuejuan ^a   Sudderth, Jessica ^b   Schulz, Eduard ^c   Deutsch, Alexander ^c   Mohan, Sumitra ^c   Ulz, Peter ^c   Neumeister, Peter ^c   Rakheja, Dinesh ^b   Gao, Xiaoli ^a   Hinck, Andrew ^a   Weintraub, Susan T ^a   DeBerardinis, Ralph J ^b   Sill, Heinz ^c   Dahia, Patricia L M ^a,d   Aguiar, Ricardo C T ^a,d,e   more..

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^f Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; D2 HYDROXYGLUTARATE; D2 HYDROXYGLUTARATE DEHYDROGENASE; DIOXYGENASE; GLUTARIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE 2; MUTANT PROTEIN; OXIDOREDUCTASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; ALCOHOL DEHYDROGENASE; ALPHA-KETOGLUTARIC ACID; D2HGDH PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; HISTONE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

CANCER; CYTOLOGY; ENZYME ACTIVITY; GENE EXPRESSION; METABOLISM; MUTATION; PATHOGENICITY; PHYSIOLOGICAL RESPONSE;

ARTICLE; CONTROLLED STUDY; DNA METHYLATION; ENZYME ACTIVITY; ENZYME REGULATION; HAPLOINSUFFICIENCY; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; LARGE CELL LYMPHOMA; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING; DIFFUSE LARGE B CELL LYMPHOMA; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HEK293 CELL LINE; METABOLISM; METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ALCOHOL OXIDOREDUCTASES; BLOTTING, WESTERN; CELL LINE, TUMOR; DIOXYGENASES; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HISTONES; HUMANS; HYDROXYLATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOCITRATE DEHYDROGENASE; KETOGLUTARIC ACIDS; LYMPHOMA, LARGE B-CELL, DIFFUSE; METHYLATION; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84937597585     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8768     Document Type: Article

References (45)

1. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465, 966 (2010).
2. Gross, S. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339-344 (2010).
3. Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alphaketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225-234 (2010).
4. Loenarz, C. & Schofield, C. J. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat. Chem. Biol. 4, 152-156 (2008).
5. Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474-478 (2012).
6. Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479-483 (2012).
7. Losman, J. A. et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621-1625 (2013).
8. Achouri, Y. et al. Identification of a dehydrogenase acting on D-2- hydroxyglutarate. Biochem. J. 381, 35-42 (2004).
9. Struys, E. A. D-2-Hydroxyglutaric aciduria: unravelling the biochemical pathway and the genetic defect. J. Inherit. Metab. Dis. 29, 21-29 (2006).
10. Kranendijk, M., Struys, E. A., Salomons, G. S., Van der Knaap, M. S. & Jakobs, C. Progress in understanding 2-hydroxyglutaric acidurias. J. Inherit. Metab. Dis. 35, 571-587 (2012).
11. Steenweg, M. E. et al. An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype-phenotype study. Hum. Mutat. 31, 380-390 (2010).
12. Rzem, R. et al. A gene encoding a putative FAD-dependent L-2- hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria. Proc. Natl Acad. Sci. USA 101, 16849-16854 (2004).
13. Moroni, I. et al. L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition? Neurology 62, 1882-1884 (2004).
14. Shim, E. H. et al. L-2-hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov. 4, 1290-1298 (2014).
15. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830-837 (2011).
16. Morin, R. D. et al. Frequent mutation of histone-modifying genes in non- Hodgkin lymphoma. Nature 476, 298-303 (2011).
17. Lohr, J. G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl Acad. Sci. USA 109, 3879-3884 (2012).
18. Zhang, J. et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 110, 1398-1403 (2013).
19. Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25-38 (2011).
20. Cimmino, L. et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat. Immunol. 16, 653-662 (2015).
21. Pasqualucci, L. The genetic basis of diffuse large B-cell lymphoma. Curr. Opin. Hematol. 20, 336-344 (2013).
22. Carey, B. W., Finley, L. W., Cross, J. R., Allis, C. D. & Thompson, C. B. Intracellular alpha-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518, 413-416 (2014).
23. Chin, R. M. et al. The metabolite alpha-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature 510, 397-401 (2014).
24. Ward, P. S. et al. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 31, 2491-2498 (2012).
25. Kranendijk, M. et al. Evidence for genetic heterogeneity in D-2-hydroxyglutaric aciduria. Hum. Mutat. 31, 279-283 (2010).
26. Ma, S. et al. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. Oncotarget 6, 8606-8620 (2015).
27. Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30 (2011).
28. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
29. Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116-120 (2012).
30. Kranendijk, M. et al. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science 330, 336 (2010).
31. Li, C. et al. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 113, 6681-6690 (2009).
32. Rai, D., Kim, S. W., McKeller, M. R., Dahia, P. L. & Aguiar, R. C. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc. Natl Acad. Sci. USA 107, 3111-3116 (2010).
33. Qin, Y. et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat. Genet. 42, 229-233 (2010).
34. Soding, J., Biegert, A. & Lupas, A. N. The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res. 33, W244-W248 (2005).
35. Arnold, K., Bordoli, L., Kopp, J. & Schwede, T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22, 195-201 (2006).
36. Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
37. Kim, S. W. et al. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alphainduced protein 3 (TNFAIP3, A20). Proc. Natl Acad. Sci. USA 109, 7865-7870 (2012).
38. Kim, S. W., Rai, D., McKeller, M. R. & Aguiar, R. C. Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL. Blood 113, 6153-6160 (2009).
39. Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385-388 (2012).
40. Contreras-Shannon, V., Lin, A. P., McCammon, M. T. & McAlister-Henn, L. Kinetic properties and metabolic contributions of yeast mitochondrial and cytosolic NADP+-specific isocitrate dehydrogenases. J. Biol. Chem. 280, 4469-4475 (2005).
41. Koivunen, P. et al. Transformation by the (R)-enantiomer of 2- hydroxyglutarate linked to EGLN activation. Nature 483, 484-488 (2012).
42. Struys, E. A., Jansen, E. E., Verhoeven, N. M. & Jakobs, C. Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride. Clin. Chem. 50, 1391-1395 (2004).
43. Rakheja, D. et al. Papillary thyroid carcinoma shows elevated levels of 2- hydroxyglutarate. Tumour Biol. 32, 325-333 (2011).
44. Rakheja, D., Mitui, M., Boriack, R. L. & DeBerardinis, R. J. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. Pediatr. Blood Cancer 56, 379-383 (2011).
45. Cheng, T. et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc. Natl Acad. Sci. USA 108, 8674-8679 (2011).